<DOC>
	<DOC>NCT00186277</DOC>
	<brief_summary>To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.</brief_summary>
	<brief_title>Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer</brief_title>
	<detailed_description>To test the combination of oxaliplatin chemotherapy in combination with taxotere chemotherapy in patients with advanced bladder cancer who have failed one prior chemotherapy.</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patient Population Type: Advanced Muscle Invasive Bladder Cancer Prior Therapy: One prior therapy for advanced disease Disease: Measurable disease ECOG Performance: 0,1 Indication: Histologically Proven Carcinoma of the bladder For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception Allergies: No known allergy to one of the study drugs Patient Status: No CNS metastases No peripheral neuropathy &gt; grade1 No other serious concomitant illness Fully recovered from any prior therapy Informed Consent: Patient and doctor have signed informed consent Lower Age Limit: Lower age limit &gt;18 Upper Age Limit: Upper Age Limit &lt;70 ANC: ANC &gt;1500/mm3 or WBC &gt; 3000/mm3 Platelets: Platelets &gt;100,000/mm3 Creatinine: Creatinine &lt;1.8mg/dL Bilirubin: Bilirubin &lt;=2.0 x ULN SGPT: SGPT (ALT) &lt;=1.5 x ULN (&lt;4xULN if liver metastases present) RBC: Hemoglobin &gt; 9.0g/dL Cardiovascular: No active congestive heart failure, no uncontrolled angina, no myocardial infarction within the past 6 months Patients with metastatic cancer of the urothelial tract (TCC, Adenocarcinoma) No prior exposure to Oxaliplatin No cytotoxics or radiation 4 weeks prior to enrolling on protocol PT/PTT normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>